ALK and neuroblastoma: In order to explore de novo mutations occurring during development of ALK inhibitor resistance, we cultivated NBLW-R neuroblastoma cells (ALKF1174L, MYCN-amplified) with increasing concentrations of lorlatinib or ceritinib for a period of 3 months (Fig. 3a) to generate resistant cell lines.